Track topics on Twitter Track topics that are important to you
Final results from the ACTIVExtend trial show sustained reductions with the osteoanabolic drug for 2 years after switching to a bisphosphonate, an effect that one expert commented is "impressive."
Medscape Medical News
Original Article: Abaloparatide Fracture Reductions Sustained in OsteoporosisNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...